| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.62B | 1.57B | 1.91B | 2.25B | 2.17B |
| Gross Profit | 343.02M | 406.39M | 506.06M | 602.14M | 560.32M |
| EBITDA | 2.05M | -3.54M | 11.46M | 115.61M | 96.00M |
| Net Income | -47.96M | -125.75M | -14.17M | 62.27M | 61.63M |
Balance Sheet | |||||
| Total Assets | 638.67M | 675.38M | 899.38M | 1.02B | 1.03B |
| Cash, Cash Equivalents and Short-Term Investments | 24.51M | 22.54M | 61.88M | 72.05M | 49.90M |
| Total Debt | 170.60M | 66.53M | 61.34M | 62.56M | 67.02M |
| Total Liabilities | 364.11M | 360.02M | 441.51M | 523.09M | 540.16M |
| Stockholders Equity | 274.56M | 315.36M | 457.87M | 496.31M | 493.07M |
Cash Flow | |||||
| Free Cash Flow | -73.72M | -41.21M | 3.48M | 89.88M | -14.57M |
| Operating Cash Flow | -58.04M | -17.06M | 34.75M | 120.50M | 20.44M |
| Investing Cash Flow | -16.06M | -2.45M | -32.32M | -20.95M | -16.22M |
| Financing Cash Flow | 57.14M | -17.09M | -37.58M | -64.69M | -19.13M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $167.93M | 23.47 | 11.08% | 2.55% | -12.65% | 368.36% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
60 Neutral | $68.43M | -8.06 | -14.43% | 41.67% | -36.79% | -507.05% | |
59 Neutral | $122.77M | -9.45 | -12.89% | ― | -9.13% | -1032.39% | |
56 Neutral | $339.12M | -1.29 | -23.06% | 3.53% | 0.46% | -477.90% | |
56 Neutral | $72.52M | 124.50 | -0.08% | ― | 1.24% | 97.14% | |
44 Neutral | $124.76M | -2.58 | -8.91% | ― | -5.37% | 75.32% |
On Feb. 18, 2025, TrueBlue reported fourth-quarter 2025 revenue of $418 million, up 8% year over year, including $14 million from its January 2025 HSP acquisition, but the net loss widened to $32 million from $12 million, driven in part by an $18 million non-cash impairment tied to a Chicago support center sublease. SG&A fell 11% to $95 million, adjusted EBITDA slid to $2 million from $9 million, and quarter-end liquidity stood at $92 million with reduced debt, while full-year 2025 revenue rose 3% to $1.6 billion and the annual net loss per diluted share narrowed to $1.61 from $4.17, as management emphasized disciplined execution of its margin-improvement and growth strategy amid stabilizing demand trends.
The most recent analyst rating on (TBI) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Trueblue stock, see the TBI Stock Forecast page.
On January 30, 2026, TrueBlue, Inc. amended its existing syndicated credit agreement, converting it from a cash-flow based revolving facility to an asset-based lending structure that ties borrowing capacity to a defined borrowing base of eligible accounts and unbilled receivables, subject to availability reserves and evolving covenant triggers tied to excess availability and fixed charge coverage. The Second Amendment reduces the company’s revolving line of credit commitment from $255 million to $175 million, while preserving an option to upsize by $150 million with lender approval and leaving pricing, sub-limits, collateral security, and maturity terms unchanged, signaling a shift toward collateral-focused financing that may influence TrueBlue’s liquidity management and covenant profile without materially altering its cost of capital.
The most recent analyst rating on (TBI) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Trueblue stock, see the TBI Stock Forecast page.
On January 12, 2026, TrueBlue, Inc. appointed Brian Capone as Senior Vice President and Chief Accounting Officer, succeeding Carl Schweihs in the principal accounting role while Schweihs remains Executive Vice President and Chief Financial Officer. Capone brings extensive experience from prior senior accounting and controller positions at Avaya, embecta Corp., Cantel Medical, Stryker, and Quest Diagnostics, and his employment terms include a $315,000 base salary, performance-based equity and cash bonus opportunities starting in 2027, and a one-time cash award vesting over four years, underscoring TrueBlue’s emphasis on strengthening its financial leadership and governance without any disclosed conflicts of interest or related-party arrangements.
The most recent analyst rating on (TBI) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Trueblue stock, see the TBI Stock Forecast page.
On January 8, 2025, TrueBlue issued a statement responding to director nominations from EHS Management, asserting that its existing strategic plan is improving financial results and positioning the company for sustainable, profitable growth in the staffing market. The company highlighted recent board refresh efforts, including the appointments of William Greenblatt and William Seward and the planned retirement of two current directors by or before the 2026 annual meeting, a process it said was informed by extensive shareholder engagement and endorsed by its largest shareholder. TrueBlue emphasized that its current board brings deep industry, operational, and financial expertise aligned with its technology-led workforce strategy, criticized EHS’s planned proxy contest as costly and disruptive, and told investors no immediate action is required ahead of the company’s forthcoming proxy materials for the 2026 shareholder meeting.
The most recent analyst rating on (TBI) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Trueblue stock, see the TBI Stock Forecast page.
On December 2, 2025, TrueBlue, Inc. announced the appointment of William Greenblatt and William Seward to its board of directors, effective January 5, 2026. This decision follows an extensive search process and reflects TrueBlue’s commitment to strengthening its board with experienced leaders to support its strategic growth and transformation. Mr. Greenblatt, a pioneer in background screening, and Mr. Seward, a seasoned executive in logistics and supply chain, bring valuable expertise to the board. The appointments are part of TrueBlue’s ongoing efforts to evolve its board composition, enhance operational oversight, and align with shareholder feedback, with two current directors expected to step down by the 2026 Annual Meeting of Shareholders.
The most recent analyst rating on (TBI) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Trueblue stock, see the TBI Stock Forecast page.